Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative-Reference-Cited by-同舟云学术

Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative

Published:2021-07-14 Issue:8 Volume:7 Page:2546-2564
ISSN:2373-8227
Container-title:ACS Infectious Diseases
language:en
Short-container-title:ACS Infect. Dis.

Author:

Malladi Sameer Kumar¹,Patel Unnatiben Rajeshbhai²,Rajmani Raju S.¹,Singh Randhir²,Pandey Suman²,Kumar Sahil³,Khaleeq Sara¹,van Vuren Petrus Jansen⁴,Riddell Shane⁴,Goldie Sarah⁴,Gayathri Savitha¹,Chakraborty Debajyoti¹,Kalita Parismita¹,Pramanick Ishika¹,Agarwal Nupur²,Reddy Poorvi²,Girish Nidhi²,Upadhyaya Aditya²,Khan Mohammad Suhail¹,Kanjo Kawkab¹,Bhat Madhuraj²,Mani Shailendra⁵,Bhattacharyya Sankar⁵,Siddiqui Samreen⁶,Tyagi Akansha⁶,Jha Sujeet⁶,Pandey Rajesh⁷,Tripathi Shashank⁸⁹,Dutta Somnath¹,McAuley Alexander J.⁴,Singanallur Nagendrakumar Balasubramanian⁴,Vasan Seshadri S.⁴¹⁰,Ringe Rajesh P.³,Varadarajan Raghavan¹^ORCID

Affiliation:

1. Molecular Biophysics Unit (MBU), Indian Institute of Science, Bengaluru 560012, India

2. Mynvax Private Limited, ES12, Entrepreneurship Centre, SID, Indian Institute of Science, Bengaluru 560012, India

3. Virology Unit, Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Sector 39-A, Chandigarh 160036, India

4. Australian Centre for Disease Preparedness (ACDP), Commonwealth Scientific and Industrial Research Organisation (CSIRO), 5 Portarlington Road, Geelong 3220, Victoria, Australia

5. Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Third Milestone, Gurugram-Faridabad Expressway, Faridabad 121001, India

6. Max Super Speciality Hospital (A Unit of Devki Devi Foundation), Max Healthcare, Delhi 1100017, India

7. Integrative Genomics of Host-Pathogen (INGEN-HOPE) Laboratory, CSIR-Institute of Genomics and Integrative Biology (CSIR-IGIB), Mall Road, Delhi 110007, India

8. Department of Microbiology & Cell Biology, Indian Institute of Science, Bengaluru 560012, India

9. Centre for Infectious Disease Research, Indian Institute of Science, Bengaluru 560012, India

10. Department of Health Sciences, University of York, York YO10 5DD, United Kingdom

Funder

Science and Engineering Research Board

National Health and Medical Research Council

Department of Biotechnology , Ministry of Science and Technology

Bill and Melinda Gates Foundation

Fondation Botnar

Govt of India PM CARES fund

CSIR-IGIB grant

CSIROâ??s Precision Health and Responsible Innovation Future Science

Australiaâ??s Department of Finance

CSR-IISc COVID vaccine fund

Publisher

American Chemical Society (ACS)

Subject

Infectious Diseases

Link

https://pubs.acs.org/doi/pdf/10.1021/acsinfecdis.1c00276

Reference87 articles.

1. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster

2. A Novel Coronavirus from Patients with Pneumonia in China, 2019

3. WHO. Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/ (accessed Jun 21, 2021).

4. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

5. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and characterization of a multimeric recombinant protein using the spike protein receptor binding domain as an antigen to induce SARS‐CoV‐2 neutralization;Immunity, Inflammation and Disease;2024-07

2. Enhanced Immunogenicity and Protective Effects against SARS-CoV-2 Following Immunization with a Recombinant RBD-IgG Chimeric Protein;Vaccines;2024-03-27

3. Vaccine adjuvants and carriers;Advanced Vaccination Technologies for Infectious and Chronic Diseases;2024

4. Enhancing Immunogenicity of a Thermostable, Efficacious SARS-CoV-2 Vaccine Formulation through Oligomerization and Adjuvant Choice;Pharmaceutics;2023-12-12

5. Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit;Antiviral Research;2023-12